Is Genpharmasec a good stock to invest in?

Genpharmasec can be analyzed on the following key metrics - TTM P/E: 69.43 Sector P/E: 0 Dividend Yield: 0% D/E ratio: -

Genpharmasec Share Price

Sector: Chemical Manufacturing

Powered by

2.16 +0.01 (0.47%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 2.11

Today’s High 2.17

52 Week Low 1.89

52 Week High 4.32

Key Metrics

Market Cap (In Cr) 119.6
Beta -0.36
Div. Yield (%) 0
P/B 1.81
TTM P/E 69.43
Peg Ratio 5.97
Sector P/E 0
D/E 0
Open Price 2.15
Prev Close 2.15

View All Metrics

Genpharmasec Analysis

Price Analysis

1 Week

-0.47%
3 Months

6.5%
6 Month

-28.52%
YTD

-30.84%
1 Year

2.9%

Risk Meter

55% Low risk
55% Moderate risk
55% Balanced Risk
55% High risk
55% Extreme risk

Genpharmasec News

Shares of Genpharmasec Ltd closed at ₹8.71, up 9.97 per cent on Monday. Mint

Premium

Rights issue 2024: Genpharmasec shares to trade ex-rights today

1 min read . 09 Jan 2024

View More News

Genpharmasec Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
33.72

Selling/ General/ Admin Expenses Total
0.99

Depreciation/ Amortization
0.81

Other Operating Expenses Total
3.12

Total Operating Expense
34.47

Operating Income
-0.75

Net Income Before Taxes
1.88

Net Income
1.23

Diluted Normalized EPS
0.02

Period
2024

Total Revenue
30.41

Selling/ General/ Admin Expenses Total
5.89

Depreciation/ Amortization
0.04

Other Operating Expenses Total
0.23

Total Operating Expense
30.4

Operating Income
0

Net Income Before Taxes
0.25

Net Income
-0.13

Diluted Normalized EPS
0

Period
2023

Total Revenue
25.52

Selling/ General/ Admin Expenses Total
1.55

Depreciation/ Amortization
0.02

Other Operating Expenses Total
0.31

Total Operating Expense
25.28

Operating Income
0.24

Net Income Before Taxes
0.28

Net Income
1.12

Diluted Normalized EPS
0.02

Period
2022

Total Revenue
27.32

Selling/ General/ Admin Expenses Total
1.09

Depreciation/ Amortization
0.01

Other Operating Expenses Total
0.18

Total Operating Expense
27.86

Operating Income
-0.54

Net Income Before Taxes
-0.44

Net Income
-0.21

Diluted Normalized EPS
0

Period
2021

Total Revenue
21.31

Selling/ General/ Admin Expenses Total
0.74

Depreciation/ Amortization
0.01

Other Operating Expenses Total
0.18

Total Operating Expense
20.13

Operating Income
1.18

Net Income Before Taxes
1.51

Net Income
1.26

Diluted Normalized EPS
0.03

Period
2020

Total Revenue
16.5

Selling/ General/ Admin Expenses Total
0.54

Depreciation/ Amortization
0

Other Operating Expenses Total
0.07

Total Operating Expense
15.85

Operating Income
0.65

Net Income Before Taxes
1.21

Net Income
1.01

Diluted Normalized EPS
0.01

Period
2019

Total Revenue
0.38

Selling/ General/ Admin Expenses Total
0.4

Depreciation/ Amortization
0

Other Operating Expenses Total
0.06

Total Operating Expense
0.46

Operating Income
-0.09

Net Income Before Taxes
0.29

Net Income
0.23

Diluted Normalized EPS
0.01

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Genpharmasec Technical

Moving Average SMA

5 Day2.17
10 Day2.19
20 Day2.13

50 Day2.08
100 Day2.32
300 Day2.69

Genpharmasec Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Resonance Specialties
114
-1.52
-1.32
123
65
132.05

Basant Agro Tech India
13.9
0.15
1.09
24.9
11
125.88

Genpharmasec
2.16
0.01
0.47
4.32
1.89
119.6

Alkali Metals
103.23
4.15
4.19
165
75.26
105.13

Aimco Pesticides
93
-5.88
-5.95
118.5
74.99
90.98

Genpharmasec Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

21-May-25
Audited Results

24-Mar-25
Independent Director Meeting

10-Feb-25
Quarterly Results

12-Nov-24
Quarterly Results

13-Aug-24
Quarterly Results

27-Jun-24
A.G.M.

24-May-24
Audited Results

27-Mar-24
Others

26-Mar-24
Independent Director Meeting

12-Feb-24
Quarterly Results

Meeting Date
Announced on
Purpose

23-Jul-24
27-Jun-24
AGM

23-Sept-23
01-Sept-23
AGM

02-Jun-23
09-May-23
EGM

29-Sept-22
05-Sept-22
AGM

Announced on
Record Date
Ex-Rights Date
Ratio
FV
Premium
Description

05-Jun-23
09-Jan-24
09-Jan-24
1:1
1
0.75
Rights issue of equity shares of Re. 1/- in the ratio of 1:1 @ premium of Re. 0.75/-.

View All

Company Profile

ABOUT Genpharmasec

Industry Chemical Manufacturing
ISIN INE861N01036
BSE Code 531592

Genpharmasec Ltd is an India-based company, which is engaged in the distribution of the lucrative medical and diagnostics device segment. It is engaged in providing technology-based medical and diagnostics devices. The Company operates through two segments: Distribution of Diagnostic Equipment’s and Investment and trading in Securities. The Company holds rights for distribution of equipments, such as i-STAT Analyzers and its Cartridges manufactured by Abbott Point of Care, USA all over India. The Company also holds distribution rights of Sphingotec Biomarkers and Joinstar System through Rivaara Labs Private Limited.

MANAGEMENT

Sohan Chaturvedi Chief Financial Officer, Whole Time Director
Hardik Makwana Chief Compliance Officer, Whole Time Company Secretary

GENPHARMASEC SUMMARY

Genpharmasec is trading 0.47% upper at Rs 2.16 as compared to its last closing price. Genpharmasec has been trading in the price range of 2.17 & 2.11. Genpharmasec has given -30.84% in this year & -0.47% in the last 5 days.

Genpharmasec has TTM P/E ratio 69.43.

The company posted a net profit of -0.58 Crores in its last quarter.

Listed peers of Genpharmasec include Resonance Specialties (-1.32%), Basant Agro Tech India (1.09%), Genpharmasec (0.47%) etc.

Genpharmasec has a 29.98% promoter holding & 70.02% public holding.

FAQs about Genpharmasec

Genpharmasec is trading at 2.16 as on 30 May, 2025 3:26:29 PM. This is 0.47% upper as compared to its previous closing price of 2.15

The market capitalization of Genpharmasec is 119.6 Cr as on 30 May, 2025 3:26:29 PM.

The 52 wk high for Genpharmasec is 4.32 whereas the 52 wk low is 1.89

Genpharmasec can be analyzed on the following key metrics -

TTM P/E: 69.43
Sector P/E: 0
Dividend Yield: 0%
D/E ratio: -

Genpharmasec reported a net profit of 1.23 Cr in 2025.

Genpharmasec Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Genpharmasec Share Price

Price Range

Key Metrics

Genpharmasec Analysis

Genpharmasec News

Rights issue 2024: Genpharmasec shares to trade ex-rights today

Genpharmasec Financials

Forecast

Forecast

Forecast

Genpharmasec Technical

Genpharmasec Peers

Genpharmasec Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Genpharmasec

MANAGEMENT

GENPHARMASEC SUMMARY

FAQs about Genpharmasec

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue